GSTM1 and rheumatoid arthritis: In this analysis of real-world data from a large US RA registry, we observed that 6 months of continuous therapy with an IL-6R inhibitor was associated with improvements in Hb and CRP levels, regardless of the level at baseline, which were greater than improvements achieved with continuous 6-month therapy with either a TNF inhibitor or a JAK inhibitor.